Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau

Frontiers in Aging Neuroscience

Volumn 5, Issue OCT, 2013, Pages

  Dickerson, Bradford C ^a   Wolk, David A ^b,c  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Alzheimer's disease; Biomarkers; CSF biomarkers; Mild cognitive impairment; MRI

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

AGED; AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN SIZE; COMPARATIVE STUDY; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DEMENTIA; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HIPPOCAMPUS; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NERVE DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PREDICTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; SURVIVAL; VERY ELDERLY;

EID: 84895822736     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2013.00055     Document Type: Article

References (31)

1. Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., et al. (2011). The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 7, 270-279. doi: 10.1016/j.jalz.2011.03.008.
2. Bakkour, A., Morris, J. C., and Dickerson, B. C. (2009). The cortical signature of prodromal AD: regional thinning predicts mild AD dementia. Neurology 72, 1048-1055. doi: 10.1212/01.wnl.0000340981.97664.2f.
3. Bakkour, A., Morris, J. C., Wolk, D. A., and Dickerson, B. C. (2013). The effects of aging and Alzheimer's disease on cerebral cortical anatomy: specificity and differential relationships with cognition. Neuroimage 76, 332-344. doi: 10.1016/j.neuroimage.2013.02.059.
4. Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., et al. (2012). Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 367, 795-804. doi: 10.1056/NEJMoa1202753.
5. Blennow, K., Hampel, H., Weiner, M., and Zetterberg, H. (2010). Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat. Rev. Neurol. 6, 131-144. doi: 10.1038/nrneurol.2010.4.
6. Buchhave, P., Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O. (2012). Cerebrospinal fluid levels of beta-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch. Gen. Psychiatry 69, 98-106. doi: 10.1001/archgenpsychiatry.2011.155.
7. De Meyer, G., Shapiro, F., Vanderstichele, H., Vanmechelen, E., Engelborghs, S., De Deyn, P. P., et al. (2010). Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people. Arch. Neurol. 67, 949-956. doi: 10.1001/archneurol.2010.179.
8. Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., et al. (2009). The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. Cereb. Cortex 19, 497-510. doi: 10.1093/cercor/bhn113.
9. Dickerson, B. C., Wolk, D. A., and Alzheimer's Disease Neuroimaging Initiative. (2011) Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics. J. Neurol. Neurosurg. Psychiatry 82, 45-51. doi: 10.1136/jnnp.2009.199505.
10. Frisoni, G. B., Fox, N. C., Jack, C. R. Jr., Scheltens, P., and Thompson, P. M. (2010). The clinical use of structural MRI in Alzheimer disease. Nat. Rev. Neurol. 6, 67-77. doi: 10.1038/nrneurol.2009.215.
11. Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., and Minthon, L. (2006). Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228-234. doi: 10.1016/S1474-4422(06)70355-6.
12. Heister, D., Brewer, J. B., Magda, S., Blennow, K., and McEvoy, L. K. (2011). Predicting MCI outcome with clinically available MRI and CSF biomarkers. Neurology 77, 1619-1628. doi: 10.1212/WNL.0b013e3182343314.
13. Jack, C. R. Jr., Bernstein, M. A., Fox, N. C., Thompson, P., Alexander, G., Harvey, D., et al. (2008). The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 27, 685-691. doi: 10.1002/jmri.21049.
14. Jack, C. R. Jr., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., et al. (2013). Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 12, 207-216. doi: 10.1016/S1474-4422(12)70291-0.
15. Jack, C. R. Jr., Lowe, V. J., Weigand, S. D., Wiste, H. J., Senjem, M. L., Knopman, D. S., et al. (2009). Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain 132, 1355-1365. doi: 10.1093/brain/awp062.
16. Jack, C. R. Jr., Petersen, R. C., Xu, Y. C., O'Brien, P. C., Smith, G. E., Ivnik, R. J., et al. (1999). Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment. Neurology 52, 1397-1403. doi: 10.1212/WNL.52.7.1397.
17. Jack, C. R. Jr., Wiste, H. J., Vemuri, P., Weigand, S. D., Senjem, M. L., Zeng, G., et al. (2010). Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease. Brain 133, 3336-3348. doi: 10.1093/brain/awq277.
18. Knopman, D. S., Jack, C. R. Jr., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., et al. (2012) Brain injury biomarkers are not dependent on beta-amyloid in normal elderly. Ann. Neurol. doi: 10.1002/ana.23816 [Epub ahead of print].
19. Landau, S. M., Harvey, D., Madison, C. M., Reiman, E. M., Foster, N. L., Aisen, P. S., et al. (2010). Comparing predictors of conversion and decline in mild cognitive impairment. Neurology 75, 230-238. doi: 10.1212/WNL.0b013e3181e8e8b8.
20. Landau, S. M., Mintun, M. A., Joshi, A. D., Koeppe, R. A., Petersen, R. C., Aisen, P. S., et al. (2012). Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann. Neurol. 72, 578-586. doi: 10.1002/ana.23650.
21. Petersen, R. C., Aisen, P., Boeve, B. F., Geda, Y. E., Ivnik, R. J., Knopman, D. S., et al. (2013) Criteria for mild cognitive impairment due to Alzheimer's disease in the community. Ann. Neurol. doi: 10.1002/ana.23931 [Epub ahead of print].
22. Petersen, R. C., Parisi, J. E., Dickson, D. W., Johnson, K. A., Knopman, D. S., Boeve, B. F., et al. (2006). Neuropathologic features of amnestic mild cognitive impairment. Arch. Neurol. 63, 665-672. doi: 10.1001/archneur.63.5.665.
23. Prestia, A., Caroli, A., van der Flier, W. M., Ossenkoppele, R., Van Berckel, B., Barkhof, F., et al. (2013). Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology 80, 1048-1056. doi: 10.1212/WNL.0b013e3182872830.
24. Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., et al. (2009). Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann. Neurol. 65, 403-413. doi: 10.1002/ana.21610.
25. Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Trojanowski, J. Q., Shaw, L. M., et al. (2010). Serial MRI and CSF biomarkers in normal aging, MCI, and AD. Neurology 75, 143-151. doi: 10.1212/WNL.0b013e3181e7ca82.
26. Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., et al. (2009a). MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations. Neurology 73, 287-293. doi: 10.1212/WNL.0b013e3181af79e5.
27. Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., et al. (2009b). MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change. Neurology 73, 294-301. doi: 10.1212/WNL.0b013e3181af79fb.
28. Villemagne, V. L., Burnham, S., Bourgeat, P., Brown, B., Ellis, K. A., Salvado, O., et al. (2013). Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 12, 357-367. doi: 10.1016/S1474-4422(13)70044-9.
29. Visser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L. O., Freund-Levi, Y., et al. (2009). Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol. 8, 619-627. doi: 10.1016/S1474-4422(09)70139-5.
30. Wang, P. N., Lirng, J. F., Lin, K. N., Chang, F. C., and Liu, H. C. (2006). Prediction of Alzheimer's disease in mild cognitive impairment: a prospective study in Taiwan. Neurobiol. Aging 27, 1797-1806. doi: 10.1016/j.neurobiolaging.2005.10.002.
31. Wolk, D. A., Dickerson, B. C., and Alzheimer's Disease Neuroimaging Initiative. (2010). Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 107, 10256-10261. doi: 10.1073/pnas.1001412107.